{"id":2286,"date":"2025-01-06T14:56:00","date_gmt":"2025-01-06T11:56:00","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2286"},"modified":"2025-03-07T15:30:18","modified_gmt":"2025-03-07T12:30:18","slug":"santhera-enters-into-supply-and-distribution-agreement-for-agamree-vamorolone-with-clinigen-group","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/santhera-enters-into-supply-and-distribution-agreement-for-agamree-vamorolone-with-clinigen-group\/","title":{"rendered":"Santhera schliesst Liefer- und Vertriebsvereinbarung f\u00fcr AGAMREE (Vamorolone) mit der Clinigen Group ab"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Santhera Pharmaceuticals gibt die Unterzeichnung einer exklusiven Vereinbarung mit der Clinigen Group zur Versorgung und Verteilung von AGAMREE\u00ae (Vamorolone) in L\u00e4ndern bekannt, in denen das Produkt anderweitig nicht kommerziell erh\u00e4ltlich ist.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Santhera Pharmaceuticals und Clinigen Group geben bekannt, dass sie eine Liefer- und Vertriebsvereinbarung f\u00fcr AGAMREE in L\u00e4ndern unterzeichnet haben, in denen das Produkt derzeit nicht \u00fcber Santhera oder einen seiner derzeitigen Vertriebspartner kommerziell erh\u00e4ltlich ist.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Die Vereinbarung erm\u00f6glicht Patienten mit Duchenne-Muskeldystrophie (DMD) in Einzelf\u00e4llen den Zugang zu AGAMREE, wenn der behandelnde Arzt keine geeigneten Alternativen f\u00fcr m\u00f6glich h\u00e4lt und die gesetzlichen Bestimmungen dies zulassen. Dank dieser Vereinbarung erh\u00e4lt Santhera den Gro\u00dfteil der Einnahmen aus der Produktlieferung in diesen zus\u00e4tzlichen L\u00e4ndern.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.santhera.com\/assets\/files\/press-releases\/2025-01-06-Santhera_Clinigen_e-FINAL.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Mehr lesen<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE\u00ae (vamorolone) in countries where the product is not otherwise commercially available. Santhera Pharmaceuticals and Clinigen Group announce that they have signed a Supply and Distribution Agreement for AGAMREE in countries where the product can currently [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2287,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[42,111,41,43],"class_list":["post-2286","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-agamree","tag-clinigen-group","tag-santhera","tag-vamorolone"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/2286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=2286"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/2286\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/2287"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=2286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=2286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=2286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}